# Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer

Source: https://onco.cc/key-papers/paper-gray-oncotype-colon-quasar-j-clin-oncol-2011/  
OnCo record `paper-gray-oncotype-colon-quasar-j-clin-oncol-2011` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The validation of a 12-gene recurrence score in stage II colon cancer, using tumour samples from the QUASAR trial.

## Summary

In 1,436 patients with stage II colon cancer from QUASAR, three-year recurrence risks were 12, 18 and 22 per cent for the predefined low, intermediate and high recurrence risk groups. The abstract states that the treatment score was not predictive of chemotherapy benefit.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: Journal of Clinical Oncology
- Year: 2011
- DOI: 10.1200/jco.2010.32.8732
- Authors: Gray RG, Quirke P, Handley K, et al.
- Findings: Three-year recurrence 12%, 18% and 22% by risk group.; The treatment score did not predict chemotherapy benefit.
- What it means: The score separates recurrence risk after surgery but does not pick out who gains from chemotherapy.
- Caveats: Stage II only; retrospective use of trial samples.

## Sources

- Gray et al., J Clin Oncol 2011: https://doi.org/10.1200/jco.2010.32.8732
- PubMed: https://pubmed.ncbi.nlm.nih.gov/22067390/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Gene-expression prognostic assays](https://onco.cc/technologies/gene-expression-prognostic-assays/)
- drugs: [Oncotype DX Colon Recurrence Score](https://onco.cc/drugs/oncotype-dx-colon/)
- terms: [Biomarker](https://onco.cc/terms/biomarker/)

---
JSON: https://onco.cc/api/v1/entities/paper-gray-oncotype-colon-quasar-j-clin-oncol-2011.json